Although evidence regarding long-term management of CIDP is limited, the ProCID study is the largest randomized study to show that IVIg is effective as maintenance therapy in patients with CIDP. The study concluded that 1.0 g/kg IVIg is effective and well-tolerated as maintenance treatment following a 2.0 g/kg induction dose in patients with active CIDP, even in those successfully treated with corticosteroids. Further studies are needed to determine if a lower or higher maintenance dose might be beneficial in some patients.
Patients with very mild symptoms that do not significantly interfere with activities of daily living might not require treatment. However, therapy with corticosteroids or IVIg should be offered to patients with moderate or severe disability.
On the basis of very limited evidence, immunosuppressants may be considered in patients who become refractory to conventional treatment.
Learn more about medication in CIDP treatment.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Jafar Kafaie, Christopher Luzzio. Fast Five Quiz: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Management - Medscape - Aug 31, 2023.